ResMed (RMD) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.95
- EPS estimate
- $2.89
- EPS surprise
- +1.98%
- Revenue surprise
- +0.16%
- Revenue
- $1.5B
- Revenue estimate
- $1.5B
- Reported
- Aug 6, 2026
ResMed reported fiscal Q4 2026 results on August 6, 2026. Earnings per share came in at $2.95, ahead of the $2.89 estimate by 1.98%. Revenue was $1.5 billion, 0.16% above the consensus. Compared with fiscal Q4 2025, EPS rose about 16% from $2.55 and revenue rose about 15% from $1.3 billion. Both figures are the highest in the table.
The longer record shows steady growth. Annual EPS rose from $5.79 in fiscal 2022 to $6.45 in 2023, $7.73 in 2024, $9.55 in 2025 and $11.17 in fiscal 2026. That is a gain of about 93%, with 17% in the latest year. Quarterly revenue grew from $904.0 million in fiscal Q1 2022 to $1.5 billion in the latest quarter. Over the last 20 quarters, ResMed beat the EPS estimate 13 times, matched it once and missed six times. The largest beat was 10.51% in fiscal Q3 2024, and the largest miss was 9.45% in fiscal Q3 2022. All four fiscal 2026 quarters were beats.
ResMed reported fiscal Q1 between October 24 and October 30 in each of the past five years. That points to late October 2026 for the next report. It will be the first look at fiscal 2027.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Aug 6, 2026 | $2.89 | $2.95 | +1.98% | $1.5B | SEC |
| Q3 2026 | Apr 30, 2026 | $2.80 | $2.86 | +2.31% | $1.4B | SEC |
| Q2 2026 | Jan 29, 2026 | $2.74 | $2.81 | +2.73% | $1.4B | SEC |
| Q1 2026 | Oct 30, 2025 | $2.52 | $2.55 | +1.32% | $1.3B | SEC |
| Q4 2025 | Jul 31, 2025 | $2.55 | $2.55 | +0.00% | $1.3B | SEC |
| Q3 2025 | Apr 23, 2025 | $2.38 | $2.37 | −0.34% | $1.3B | SEC |
| Q2 2025 | Jan 30, 2025 | $2.32 | $2.43 | +4.94% | $1.3B | SEC |
| Q1 2025 | Oct 24, 2024 | $2.05 | $2.20 | +7.10% | $1.2B | SEC |
| Q4 2024 | Aug 1, 2024 | $2.08 | $2.08 | −0.13% | $1.2B | SEC |
| Q3 2024 | Apr 25, 2024 | $1.93 | $2.13 | +10.51% | $1.2B | SEC |
| Q2 2024 | Jan 24, 2024 | $1.78 | $1.88 | +5.84% | $1.2B | SEC |
| Q1 2024 | Oct 26, 2023 | $1.62 | $1.64 | +1.29% | $1.1B | SEC |
| Q4 2023 | Aug 3, 2023 | $1.68 | $1.60 | −4.72% | $1.1B | SEC |
| Q3 2023 | Apr 27, 2023 | $1.61 | $1.68 | +4.65% | $1.1B | SEC |
| Q2 2023 | Jan 26, 2023 | $1.61 | $1.66 | +2.82% | $1.0B | SEC |
| Q1 2023 | Oct 27, 2022 | $1.54 | $1.51 | −1.63% | $950.3M | SEC |
| Q4 2022 | Aug 11, 2022 | $1.44 | $1.49 | +3.34% | $914.7M | SEC |
| Q3 2022 | Apr 28, 2022 | $1.46 | $1.32 | −9.45% | $864.5M | SEC |
| Q2 2022 | Jan 27, 2022 | $1.50 | $1.47 | −1.73% | $894.9M | SEC |
| Q1 2022 | Oct 28, 2021 | $1.37 | $1.51 | +10.07% | $904.0M | SEC |
Quarterly revenue
Frequently asked questions
When did ResMed (RMD) last report earnings?
ResMed last reported on Aug 6, 2026, covering fiscal Q4 2026.
Did RMD beat earnings estimates?
Yes. ResMed reported EPS of $2.95 for Q4 2026 against a $2.89 estimate — a 1.98% beat.
How much revenue did RMD report last quarter?
ResMed reported $1.5B in revenue for Q4 2026, against a consensus estimate of $1.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.